Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05833763
Title A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure. (GOlDiLOX)
Acronym GOlDiLOX
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Australasian Leukaemia and Lymphoma Group
Age Groups: adult | senior
Covered Countries AUS

No variant requirements are available.